

Atty. Dkt. No. 072121-0389 (16325.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul A. Renhowe, et al.

Title:

HETEROCYCLIC COMPOUNDS

Appl. No.:

10/823,995


Filing Date: April 14, 2004

Art Unit:

1625

Examiner:

Zinna Northington Davis



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

06/05/2006 CCHAU1

00000137 502350 10823995

01 FC:1806

180.00 DA

MADI 654823.1

-1-



Atty. Dkt. No. 072121-0389 (16325.0009)

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of related European and U.S. applications. Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

The Commissioner is hereby authorized to charge the fee of \$180.00 (Fee Code 1806) set forth in 37 CFR § 1.97(c)(2) and § 1.17(p) to Deposit Account No. 50-2350. The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350..

Respectfully submitted,

Dated: June 1, 2006

FOLEY & LARDNER LLP Customer Number: 23524

Telephone:

(608) 258-4303

Facsimile:

(608) 258-4258

Joseph P. Meara

Attorney for Applicant Registration No. 44,932

MODIFIED PTO/SB/08 (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for f	form 1449B/	PTO/) \ \		Complete if Known	
	INFORMATION	N DISCLO	SŲŔE	'4	Application Number	10/823,995	
	STATEMENT	BY APPLI	CÁNT	ILIN 0 5 7006	Filing Date	4/14/2004	
Date Submitted: June 1, 2006					#rst Named Inventor	Paul A. Renhowe, et al.	
					Group Art Unit	1625	
	(use as many she	eets as ne	cessar	7)	Examiner Name	Zinna Northington Davis	
Sheet	1	of	1	MAINE	Attorney Docket Number	072121-0389 (16325.0009)	

U.S. PATENT DOCUMENTS						
Examiner Initials*	011-	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
-						

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 01/28993	Merck & Co., Inc.	4/26/2001	- * 1	
		WO 02/18383	Chiron Corporation	3/7/2002		
		WO 00/20400	Axys Pharmaceuticals, Inc.	4/13/2000		
		EP 0290153	Pfizer Limited	11/9/1988		1

NON PATENT LITERATURE DOCUMENTS					
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T-6			
	European Search Report dated February 28, 2006 for EP 05017665.0.				
	Ukrainets, et al., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," Tetrahedron Letters, Vol. 36, No. 42, 1995, pp. 7747-7748.				
	Carla Heise, et al., "In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis," Abstract and presentation material for a presentation at the American Association for Cancer Research meeting held in April, 2002.				
	4	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. European Search Report dated February 28, 2006 for EP 05017665.0. Ukrainets, et al., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," Tetrahedron Letters, Vol. 36, No. 42, 1995, pp. 7747-7748. Carla Heise, et al., "In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis," Abstract and presentation material for a presentation at the			

Examiner Signature	Date Considered	
-----------------------	--------------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.